Heterodimeric proteins

Patent metadata

Field	Value
Publication number	US-12415849-B2
Application number	US-202318463209-A
Country	US
Kind code	B2
Filing date	Sep 7, 2023
Priority date	Mar 15, 2013
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.

First claim

What is claimed is:

1. A heterodimeric protein comprising a heterodimeric Fc domain, the heterodimeric Fc domain comprising:
a) a first monomer comprising a first variant Fc domain comprising amino acid substitutions L368D, K370S, M428L and N434S; and
b) a second monomer comprising a second variant Fc domain comprising amino acid substitutions S364K, E357Q, M428L and N434S,
wherein numbering is according to EU numbering, and wherein the first variant Fc domain and the second variant Fc domain are variant human IgG Fc domains.

2. A heterodimeric protein according to claim 1 , wherein the first monomer further comprises a first fusion partner, and the second monomer further comprises a second fusion partner.

3. A heterodimeric protein according to claim 2 , wherein the first monomer comprises a third fusion partner.

4. A heterodimeric protein according to claim 3 , wherein the second monomer comprises a fourth fusion partner.

5. A heterodimeric protein according to claim 2 , wherein the fusion partners are independently selected from the group consisting of an immunoglobulin component, a peptide, a cytokine, a chemokine, an immune receptor and a blood factor.

6. A heterodimeric protein according to claim 5 , wherein the immunoglobulin component is selected from the group consisting of Fab, VH, VL, scFv, scFv2, and dAb.

7. A heterodimeric protein according to claim 5 , wherein both fusion partners are immunoglobulin components.

8. A nucleic acid composition encoding the heterodimeric protein of claim 1 comprising:
a) a first nucleic acid encoding the first monomer; and
b) a second nucleic acid encoding the second monomer.

9. An expression vector composition encoding the heterodimeric protein of claim 1 comprising:
a) a first expression vector comprising a first nucleic acid encoding the first monomer; and
b) a second expression vector comprising a second nucleic acid encoding the second monomer.

10. A host cell comprising the expression vector composition of claim 9 .

11. A method of making a heterodimeric protein comprising culturing a host cell according to claim 10 under conditions whereby a heterodimeric protein comprising a heterodimeric Fc domain is produced, and recovering the heterodimeric protein.

Assignees

• Xencor Inc

Inventors

• Moore Gregory
• Bernett Matthew
• Rashid Rumana
• Desjarlais John

Classifications

• C07K2317/64

  comprising a combination of variable region and constant region components · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K16/22

  against growth factors {; against growth regulators} · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title